**Supplemental Table 1. Baseline and one and two-year follow-up dietary and physical activity characteristics of study participants (mean values ±SD)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Overall** | **Control** | **Raloxifene 60mg** | **Raloxifene 30mg** | **Lovaza 4g** | **Raloxifene 30mg/****Lovaza 4g** | **Overall\*\*\*****Difference****(p-value)** |
| **Dietary**Energy at Baseline (kcal)Energy at 12 mo. (Kcal)Energy at 24 mo. (Kcal)Energy ∆ (kcal)\*P-value\*\* | 1501 (577)1461 (604)1436 (604)-56 (414)- | 1440 (588)1362 (475)1439 (519)4 (396)Referent | 1505 (630)1518 (772)1387 (521)-140 (440)0.19 | 1612 (651)1582 (645)1670 (792)14 (455)0.60 | 1425 (540)1460 (592)1457 (651)-27 (364)0.72 | 1543 (460)1406 (518)1454 (502)141 (423)0.16 | 0.26 |
| Carbohydrate at Baseline (%kcal)Carbohydrate at 12 mo. (%Kcal)Carbohydrate at 24 mo. (%Kcal)Carbohydrate ∆ (%kcal)\*P-value\*\* | 50.2 (8.6)49.9 (8.5)49.8 (8.2)-0.3 (6.7)- | 50.2 (8.5)50.4 (9.1)50.5 (8.3)0.0 (6.2)Referent | 49.3 (9.3)48.9 (9.5)49.6 (8.2)-0.1 (7.0)0.80 | 50.3 (8.1)49.8 (8.4)49.5 (8.1)-0.7 (5.2)0.55 | 51.8 (8.4)49.9 (7.7)48.7 (8.2)-2.3 (6.5)0.07 | 49.2 (8.9)50.4 (7.9)50.7 (8.5)1.7 (8.1)0.36 | 0.10 |
| Fat at Baseline (%kcal)Fat at 12 mo. (%Kcal)Fat at 24 mo. (%Kcal)Fat ∆ (%kcal)\*P-value\*\* | 33.3 (6.8)33.7 (7.0)33.6 (6.6)0.1 (5.8)- | 33.6 (6.6)33.4 (6.9)33.0 (6.6)-0.3 (5.6)Referent | 33.0 (7.7)32.6 (7.8)31.7 (6.5)-0.7 (5.7)0.59 | 32.7 (5.8)34.3 (7.0)34.2 (5.1)0.9 (4.7)0.23 | 32.4 (6.7)33.8 (6.7)34.3 (7.6)1.4 (6.0)0.19 | 34.9 (7.1)34.6 (6.6)34.5 (6.5)-0.9 (6.7)0.74 | 0.32 |
| Protein at Baseline (%kcal)Protein at 12 mo. (%Kcal)Protein at 24 mo. (%Kcal)Protein ∆ (%kcal)\*P-value\*\* | 16.6 (3.0)16.3 (2.8)16.4 (2.8)-0.2 (2.5)- | 16.5 (2.6)16.3 (2.7)16.2 (3.1)-0.3 (2.6)Referent | 16.8 (3.3)16.3 (3.0)16.7 (2.6)-0.1 (2.8)0.34 | 16.6 (2.5)16.0 (2.6)16.2 (2.8)-0.3 (2.3)0.99 | 16.3 (3.0)16.8 (2.9)17.0 (2.8)0.3 (2.3)0.12 | 16.6 (3.4)16.1 (3.0)16.0 (2.9)-0.5 (2.3)0.82 | 0.33 |
| n-3FA at baseline (g)n-3FA at 12 mo. (g)n-3FA at 24 mo. (g)n-3FA ∆ (g)\*P-value\*\* | 1.18 (0.64)1.17 (0.65)1.14 (0.55)-0.06 (0.42)- | 1.15 (0.58)1.13 (0.53)1.10 (0.47)-0.05 (0.39)Referent | 1.19 (0.65)1.15 (0.73)1.06 (0.55)-0.10 (0.43)0.63 | 1.24 (0.70)1.26 (0.63)1.31 (0.59)0.00 (0.46)0.08 | 1.13 (0.72)1.16 (0.70)1.12 (0.58)-0.02 (0.41)0.62 | 1.19 (0.57)1.16 (0.66)1.12 (0.54)-0.15 (0.43)0.42 | 0.13 |
| n-6FA at baseline (g)n-6FA at 12 mo. (g)n-6FA at 24 mo. (g)n-6FA ∆ (g)\*P-value\*\* | 11.8 (7.2)11.9 (7.2)11.5 (6.2)-0.6 (5.7)- | 11.2 (6.1)10.7 (5.5)11.3 (6.2)0.3 (4.8)Referent | 11.5 (7.0)12.0 (9.0)10.5 (5.7)-0.8 (4.5)0.49 | 12.4 (7.0)13.4 (7.6)13.2 (6.2)0.0 (5.0)0.27 | 11.7 (9.8)11.8 (7.7)11.7 (7.1)-0.3 (6.9)0.84 | 12.1 (5.4)11.7 (6.1)10.8 (5.5)-2.0 (6.3)0.18 | 0.17 |
| n-3FA:n-6FA BL (ratio) baselinen-3FA:n-6FA 12 mo.n-3FA:n-6FA 24 mo.n-3FA:n-6FA ∆\*P-value\*\* | 0.11 (0.03)0.11 (0.04)0.11 (0.03)0.00 (0.03)- | 0.11 (0.03)0.11 (0.04)0.11 (0.04)0.00 (0.03)Referent | 0.11 (0.03)0.10 (0.02)0.11 (0.03)0.00 (0.03)0.79 | 0.11 (0.05)0.11 (0.08)0.11 (0.05)0.00 (0.02)0.76 | 0.10 (0.03)0.10 (0.03)0.11 (0.03)0.00 (0.02)0.95 | 0.10 (0.03)0.10 (0.02)0.11 (0.04)0.00 (0.03)0.37 | 0.88 |
| **Overall physical activity** Baseline (Mets/d) 12 months (Mets/d) 24 months (Mets/d) Activity ∆ (Mets/d)\* P-value\*\* | 819 (1126)792 (817)779 (779)-60 (1120)- | 643 (552)801 (692)760 (710)100 (820)Referent | 608 (509)849 (1066)710 (506)59 (474)0.91 | 1123 (1399)749 (764)817 (715)-670 (1887)0.44 | 755 (822)725 (727)782 (860)115 (901)0.78 | 956 (1735)848 (880)818 (983)-36 (1064)0.49 | 0.87 |

\*Change (∆) is calculated as 24 mo. – Baseline

\*\*Test of the change over time (baseline to 24 mo.) with the selected group compared to the control group (referent).

\*\*\*Overall test of difference over time (baseline to 24 mo.) across groups.